1.

Baseline characteristics of patients given AC or PC with or without bevacizumab (N=1,534)

Variables	n (%)			P
	AC (N=670)	PC without bevacizumab (N=356)	PC with bevacizumab (N=508)
AC, adjuvant chemotherapy; PC, palliative chemotherapy; BMI, body mass index; FOLFOX, folinic acid, fluorouracil (5-FU), oxaliplatin; FOLFIRI; folinic acid, fluorouracil (5-FU), irinotecan; *, preoperative chemoradiotherapy for rectal cancer or lost to follow-up.
Sex				0.313
Male	397 (59.3)	227 (63.8)	301 (59.3)
Age (year)
Median (range)	58 (20–83)	59 (18–84)	57 (29–85)	0.514
>65	196 (29.3)	115 (32.3)	138 (27.2)	0.264
BMI (kg/m2)				0.011
>30	7 (1.0)	13 (3.7)	8 (1.6)
Chemotherapy regimen				<0.001
FOLFOX	619 (92.4)	132 (37.3)	198 (39.0)
FOLFIRI	0 (0)	201 (56.8)	310 (61.0)
Others	51 (7.6)*	23 (6.5)	0 (0)
Clinical setting				<0.001
Adjuvant setting	670 (100)	0 (0)	0 (0)
Palliative first line setting	0 (0)	350 (98.3)	496 (97.6)
Palliative second or third line setting	0 (0)	6 (1.7)	12 (2.4)
Number of metastatic sites				<0.001
0	670 (100)	0 (0)	0 (0)
1	0 (0)	221 (62.1)	236 (46.5)
2	0 (0)	88 (24.7)	167 (32.9)
≥3	0 (0)	47 (13.2)	105 (20.7)
Aspirin or other antiplatelet or anticoagulant drug during treatment	8 (1.2)	7 (2.0)	5 (1.0)	0.432
Prior surgery				<0.001
Primary site resection	670 (100)	257 (72.2)	358 (70.5)
Metastasectomy	0 (0)	77 (21.6)	103 (20.3)
Palliative diversion (i.e., ileostomy and 　colostomy)	0 (0)	23 (6.5)	33 (6.5)
Prior chemotherapy	0 (0)	108 (30.3)	117 (23.0)	<0.001
Previous history/complication
Thromboembolic events	4 (0.6)	8 (2.2)	5 (1.0)	0.053
Hypertension	210 (31.3)	120 (33.7)	164 (32.3)	0.742
Diabetes	91 (13.6)	53 (14.9)	62 (12.2)	0.517
Cardiovascular disease	28 (4.2)	22 (6.2)	20 (3.9)	0.244
Hyperlipidemia	17 (2.5)	5 (1.4)	13 (2.6)	0.450
Abnormal liver function	28 (4.2)	17 (4.8)	21 (4.1)	0.881
Prior anticoagulation therapy	15 (2.2)	12 (3.4)	13 (2.6)	0.555